First-Line Axi-Cel Appears Effective in High-Risk Large B-Cell Lymphoma
At a median follow-up of 15.9 months, the median duration of response was not reached.
At a median follow-up of 15.9 months, the median duration of response was not reached.
The “myTcell” app is expected to be released in the United States in 2022.
There was 1 case of grade 3 CRS and 1 case of grade 4 CRS.
Outcomes were similar to those seen in the ZUMA-2 trial.
Sixty-seven percent of rehospitalizations occurred within the first month of CAR T-cell infusion.
Axicabtagene ciloleucel was associated with higher rates of grade 3-5 ICANS and corticosteroid use.
Minimal residual disease in the bone marrow, detected via next-generation sequencing, was “highly predictive” of relapse after treatment with tisagenlecleucel.
Researchers sought to determine whether patients with B-ALL who progress after CAR-T therapy would have a poor prognosis.
CHIP was associated with higher rates of complete response and cytokine release syndrome.
Researchers sought to determine whether plasma biomarkers may help enhance CAR-T therapy for patients with multiple myeloma.